An interventional study of Clinical Pharmacist-Led Pharmaceutical Care in Major Depressive Disorder (MDD) and Medication Adherence, sponsored by Marmara University. Completed at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by Marmara University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 32 studies in Depressive Disorder, Major with a site in Turkey — 14 open to participants now, 15 under way, 1 of them phase 3. Depressive Disorder, Major · Turkey.
Among the 32 studies in Depressive Disorder, Major with a site in Turkey, this one is the 9th largest by enrollment of the 24 interventional ones that give a count, is one of 7 that started in 2024, is one of 11 with no phase, and was the 32nd registered.
3,050 studies on the registry are indexed under Depressive Disorder, Major; 594 are open to participants now.
Browse Depressive Disorder, Major studies →14 of the 32 studies in Depressive Disorder, Major with a site in Turkey are open now. Recruiting first, the newest first:
Gulhane Training and Research Hospital · Sites in Turkey
Ages 18–55 · Healthy volunteers
Medipol University · Sites in Turkey
Ages 18–65
Istanbul University - Cerrahpasa · Sites in Turkey
Ages 18–65
Istanbul University - Cerrahpasa · Sites in Turkey
Ages 18–60 · Healthy volunteers
Istanbul University - Cerrahpasa · Sites in Turkey
Ages 55+ · Healthy volunteers
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 415 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 295 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
32 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 7 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 186 is above the median of 80 across 2,536 interventional studies indexed under Depressive Disorder, Major.
Median enrollment 95 across the 24 interventional studies, 78 across the 8 observational. Of the 16 that completed or were terminated, 7 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 32 have an industry lead sponsor. The 10 most frequent:
Marmara University is the lead sponsor of 600 studies on the registry; 138 are open to participants now.
Marmara University has 1 study filed under Depressive Disorder, Major — fewer than ten, so there is no comparison to draw.
11 of the studies in Depressive Disorder, Major with a site in Turkey that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06559306Phase 3Janssen Research & Development, LLCPhase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms | 2026-12-30 |
| NCT07534475Medipol UniversityVenous Tourniquet vs. Arterial Tourniquet for Seizure Monitoring in ECT | 2026-11-30 |
| NCT07748091Istanbul University - CerrahpasaEEG Microstate Parameters and Neuroinflammatory Biomarkers in Patients With Treatment-Resistant Major Depressive Disorder Receiving ECT | 2026-12 |
| NCT07740694Istanbul University - CerrahpasaEEG Microstate and Neuroinflammatory Biomarkers in Older Age Patients With Major Depressive Disorder Receiving ECT | 2026-12 |
| NCT07603804Istanbul University - CerrahpasaAccelerated iTBS for Major Depression | 2026-12 |
Add all 11 to your calendar (.ics) → With an account.
Among the 32 studies in Depressive Disorder, Major with a site in Turkey, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This randomized controlled trial evaluated the effects of a six-month clinical pharmacist-led pharmaceutical care intervention on medication adherence, beliefs about medicines, and health-related quality of life in adults diagnosed with major depressive disorder (MDD) receiving antidepressant treatment.
A total of 186 participants were randomized in a 1:1 ratio to receive either structured pharmaceutical care in addition to usual psychiatric care or usual psychiatric care alone. Of these, 170 participants completed the six-month follow-up.
The intervention included individualized patient counseling, medication review, identification and management of medication-related problems, and telephone follow-up every two weeks.
Medication adherence was assessed using the Medication Adherence Report Scale (MARS-5), beliefs about medicines using the Turkish Beliefs about Medicines Questionnaire (BMQ-T), and health-related quality of life using the EQ-5D-3L and EQ-VAS. Assessments were conducted at baseline, Month 3, and Month 6.
This prospective, single-center, open-label, parallel-group randomized controlled trial was conducted at a psychiatry outpatient clinic affiliated with Marmara University in Istanbul, Türkiye. Eligible adults were 18-65 years old, met DSM-IV or DSM-5 criteria for major depressive disorder, and had received antidepressant medication for at least one month. Participants were allocated in a 1:1 ratio using a computer-generated simple randomization sequence. According to the manuscript, allocation was performed by an independent administrative staff member not involved in enrollment, intervention, follow-up, or outcome assessment, and the allocation sequence was concealed from the recruiting investigator until eligibility and enrollment were completed. The intervention group received individualized clinical pharmacist-led pharmaceutical care in addition to usual psychiatric care. The care included education and counseling, medication history review, assessment of medication-related problems and adverse effects, identification of adherence barriers, an individualized care plan, collaboration with the treating psychiatrist as needed, and contact by telephone or message every 15 days for six months. The control group received usual psychiatrist-led care without the structured pharmacist intervention during follow-up. Outcome assessments occurred at baseline, Month 3, and Month 6. A total of 186 participants were randomized (93 per group), and 170 completed six-month follow-up (84 intervention; 86 control).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants assigned to this group received structured clinical pharmacist-led pharmaceutical care in addition to usual psychiatric care for six months. The intervention included individualized patient education and counseling, medication review, identification and management of medication-related problems, monitoring of adverse effects, and telephone follow-up every two weeks.
Other: Clinical Pharmacist-Led Pharmaceutical Care
Participants assigned to the control group received usual psychiatric care, including routine clinical follow-up and antidepressant treatment as prescribed by their treating psychiatrist. No additional structured clinical pharmacist-led pharmaceutical care intervention was provided during the six-month study period. Outcome assessments were conducted at baseline, Month 3, and Month 6.
A structured six-month clinical pharmacist-led pharmaceutical care intervention consisting of individualized patient counseling, medication review, identification and management of medication-related problems, monitoring of adverse effects, and telephone follow-up every two weeks, provided in addition to usual psychiatric care.
Change in Medication Adherence as Measured by MARS-5
Medication adherence was assessed using the five-item Medication Adherence Report Scale (MARS-5). Each item is scored from 1 to 5, yielding a total score ranging from 5 to 25. Higher scores indicate better medication adherence. Changes in total MARS-5 scores were assessed at baseline, Month 3, and Month 6 to evaluate the effectiveness of the clinical pharmacist-led pharmaceutical care intervention.
Time frame: Baseline, Month 3, and Month 6
Change in Beliefs About Medicines - Specific Necessity
Beliefs about the necessity of prescribed antidepressant medication were assessed using the Specific Necessity subscale of the Turkish Beliefs about Medicines Questionnaire (BMQ-T). Scores range from 5 to 25, with higher scores indicating stronger perceived necessity of medication.
Time frame: Baseline, Month 3, and Month 6
Change in Beliefs About Medicines - Specific Concerns
Concerns about prescribed antidepressant medication were assessed using the Specific Concerns subscale of the Turkish Beliefs about Medicines Questionnaire (BMQ-T). Scores range from 5 to 25, with higher scores indicating greater concerns about medication use.
Time frame: Baseline, Month 3, and Month 6
Change in Beliefs About Medicines - General Overuse
General beliefs regarding the overuse of medicines by physicians were assessed using the General Overuse subscale of the Turkish Beliefs about Medicines Questionnaire (BMQ-T). Scores range from 4 to 20, with higher scores indicating stronger beliefs that medicines are overprescribed.
Time frame: Baseline, Month 3, and Month 6
Change in Beliefs About Medicines - General Harm
General beliefs about the harmful effects of medicines were assessed using the General Harm subscale of the Turkish Beliefs about Medicines Questionnaire (BMQ-T). Scores range from 4 to 20, with higher scores indicating stronger beliefs that medicines are harmful.
Time frame: Baseline, Month 3, and Month 6
Change in Health-Related Quality of Life (EQ-5D-3L Index)
Health-related quality of life was assessed using the EuroQol 5-Dimension 3-Level questionnaire (EQ-5D-3L). Responses across five dimensions were converted into a health utility index using a value set. Higher index values indicate better health-related quality of life.
Time frame: Baseline, Month 3, and Month 6
Change in Self-Rated Health Status (EQ-VAS)
Self-rated health status was assessed using the EuroQol Visual Analogue Scale (EQ-VAS), ranging from 0 (the worst imaginable health) to 100 (the best imaginable health). Higher scores indicate better self-perceived health status.
Time frame: Baseline, Month 3, and Month 6
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Dec 2024 to primary completion in Mar 2026, 15 months.
Of 653 non-industry interventional studies with no phase under Depressive Disorder, Major, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 55. This study's 15 months is below that.
Counting every sponsor, half of 693 studies reached it within 33 months; a quarter within 17 and three quarters within 55.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.